Tag Archives: section 3(d)

10 September, 2014- In a move towards furthering access to affordable medicines, Lawyers Collective through Sankalp Rehabilitation Trust, the Hepatitis Coalition of Nagaland and Network of PLHIV living in the Asia Pacific region (APN+), filed a pre- grant challenge to sofosbuvir (Sovaldi) in India. The opposition is against the pro-drug patent application 3658/kolnp/2009 which is…

30th January, 2014: The Intellectual Property Appellate Board (IPAB) set aside the Patent Controller’s decision to revoke the patent relating to valganciclovir on technical grounds and remanded it to the Controller for re-consideration. In a significant development for patient groups, the IPAB rejected the demand of the patentee, Hoffman La Roche, to restore the patent…

Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a hearing, ‘A tangle of trade barriers’ before the US Energy and Commerce Committee saw witness testimonies including that…

Vol – XLVIII No. 32, August 10, 2013 | Anand Grover A detailed account of the examination of Section 3(d) of the Indian Patents Act in the Supreme Court’s judgment on Novartis’s patent application for Glivec. Anand Grover (anandgrover@gmail.com) is a Senior Advocate practising in the Supreme Court and the Director of the Lawyers Collective. He and…

Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world 10 April, 2013, New Delhi­- Thousands of people living with HIV, cancer patient groups & public health activists rallied on the streets of Delhi today calling on the Indian government to reject the EU’s…

Novartis threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent for its drug Gleevec, Novartis itself has threatened that it will not register any new…

[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and against Indian Patent law has finally reached a conclusion. On Apr1, Indian Supreme court dismissed…